Back to top
more

AbbVie (ABBV)

(Real Time Quote from BATS)

$199.92 USD

199.92
334,794

-0.55 (-0.27%)

Updated Nov 5, 2024 10:30 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

J&J's (JNJ) Q4 Earnings Beat, 2019 Sales Forecast Soft

by Zacks Equity Research

J&J (JNJ) beats estimates for both earnings and sales in the fourth quarter of 2018, leading to an increase in shares in pre-market trading. 2019 sales guidance falls short of expectations.

Bet on These 5 Low Leverage Stocks to Secure Returns

by Zacks Equity Research

A high degree of financial leverage means high interest payments, which affect the company's bottom line. So, investors try to avoid stocks that bear large debt loads

AbbVie's Imbruvica Fails in Phase III Pancreatic Cancer Study

by Zacks Equity Research

AbbVie's (ABBV) Imbruvica falls short of meeting the primary endpoint of PFS or OS benefit in a phase III study that probed its combo usage in first-line metastatic pancreatic cancer.

Zacks Value Trader Highlights: Crocs, Five Below, AbbVie and J.Jill

by Zacks Equity Research

Zacks Value Trader Highlights: Crocs, Five Below, AbbVie and J.Jill

What's in Store for Bristol-Myers (BMY) in Q4 Earnings?

by Zacks Equity Research

Performance of Opdivo and the recently announced acquisition of Celgene Corporation will be key areas of focus for the investors when Bristol-Myers (BMY) reports fourth-quarter results.

AbbVie (ABBV) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

AbbVie (ABBV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Can AbbVie (ABBV) Keep the Earnings Surprise Streak Alive?

by Zacks Equity Research

AbbVie (ABBV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Tracey Ryniec headshot

Are you a Tortoise or a Hare Investor?

by Tracey Ryniec

Some love the latest IPO and others invest in the tried and true. All investors should know their investing style

Madhu Goel headshot

Pacira's Study on Exparel Label Expansion Meets Endpoints

by Madhu Goel

Pacira's (PCRX) phase IV study of its lead drug Exparel in patients undergoing Cesarean section achieves primary endpoint.

Zacks Market Edge Highlights: Occidental, Gilead, AbbVie, AT&T and Verizon

by Zacks Equity Research

Zacks Market Edge Highlights: Occidental, Gilead, AbbVie, AT&T and Verizon

Kitov Pharma's Stock Up on Anti-Cancer Candidate Findings

by Zacks Equity Research

Shares of Kitov Pharma (KTOV) soar about 169% as the company's anti-cancer candidate, NT219 shows positive results.

Tracey Ryniec headshot

Will Dividend Stocks be the Hot Stocks of 2019?

by Tracey Ryniec

With growth stocks sputtering to end 2018, investors seem poised to look in a new direction.

Top Ranked Growth Stocks to Buy for January 14th

by Zacks Equity Research

Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, January 14th

5 Reasons Why Investors Should Buy Novo Nordisk (NVO) in 2019

by Zacks Equity Research

Novo Nordisk (NVO) has a strong presence in the Diabetes care market and its top line is driven by strong performance of products like Victoza.

Pharma Stock Roundup: Lilly to Buy Loxo for $8B, M&A in Focus at JP Morgan Meet

by Zacks Equity Research

Lilly (LLY) is spending $8 billion to buy small cancer biotech Loxo Oncology. Big Pharma CEOs hint at spur in M&A activity in 2019.

Top Ranked Momentum Stocks to Buy for January 11th

by Zacks Equity Research

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, January 11th:

Top Ranked Momentum Stocks to Buy for January 10th

by Zacks Equity Research

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, January 10th:

Is AbbVie (ABBV) a Great Value Stock Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

The Zacks Analyst Blog Highlights: Visa, Coca-Cola, AbbVie, Johnson & Johnson and Duke Energy

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Visa, Coca-Cola, AbbVie, Johnson & Johnson and Duke Energy

Novartis' Crizanlizumab Gets Breakthrough Therapy Status

by Zacks Equity Research

Novartis's (NVS) crizanlizumab gets Breakthrough Therapy designation by the FDA for the prevention of VOCs in patients of all genotypes with SCD.

Top Ranked Momentum Stocks to Buy for January 8th

by Zacks Equity Research

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, January 8th:

Mark Vickery headshot

Top Analyst Reports for Visa, Coca-Cola & AbbVie

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Visa (V), Coca-Cola (KO) and AbbVie (ABBV).

AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

AbbVie (ABBV) closed at $90.40 in the latest trading session, marking a +1.49% move from the prior day.

Neurocrine Gives Ingrezza Sales View, Updates on Pipeline

by Zacks Equity Research

Neurocrine (NBIX) issues preliminary sales outlook for Ingrezza with respect to the fourth quarter of 2018 as well as the full year. The company also lends an update on its pipeline.

Gilead (GILD) Collaborates With Yuhan for NASH Candidates

by Zacks Equity Research

Gilead (GILD) collaborates with Korean company Yuhan for the development of NASH treatments.